Brief: Orthocell's Application In Singapore Accepted For Review By HSA
29/07/2024 02:30
July 29 (Reuters) - Orthocell Ltd OCC.AX :
* APPLICATION TO MARKET AND SELL GUIDED BONE AND TISSUE
REPAIR
PRODUCT IN SINGAPORE ACCEPTED FOR REVIEW BY HSA SINGAPORE
Further company coverage: OCC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orthocell
See all newsBrief: Orthocell Reports September Quarter Revenue Of A$3.6 Million
Australia's Orthocell rises as flagship product records first Thailand sales
Brief: Orthocell Says QTRLY A$3.2 Million Revenue Achieved
Australia's Orthocell set for best week since November 2024 on US DoD approval for key product
Brief: Orthocell's First Surgical Use Of Remplir In US Department Of Defense